HK1198646A1 - Substituted imidazopyridines and the use thereof - Google Patents

Substituted imidazopyridines and the use thereof

Info

Publication number
HK1198646A1
HK1198646A1 HK14112109.7A HK14112109A HK1198646A1 HK 1198646 A1 HK1198646 A1 HK 1198646A1 HK 14112109 A HK14112109 A HK 14112109A HK 1198646 A1 HK1198646 A1 HK 1198646A1
Authority
HK
Hong Kong
Prior art keywords
substituted imidazopyridines
imidazopyridines
substituted
Prior art date
Application number
HK14112109.7A
Other languages
English (en)
Chinese (zh)
Inventor
Markus Follmann
Johannes-Peter Stasch
Gorden Redlich
Alexander Straub
Jens Ackerstaff
Nils Griebenow
Andreas Knorr
Frank Wunder
Volkhart Min-Jian Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198646A1 publication Critical patent/HK1198646A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK14112109.7A 2011-05-06 2014-12-02 Substituted imidazopyridines and the use thereof HK1198646A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102011075398A DE102011075398A1 (de) 2011-05-06 2011-05-06 Substituierte Imidazopyridazine und ihre Verwendung
PCT/EP2012/058048 WO2012152630A1 (fr) 2011-05-06 2012-05-02 Imidazopyridazines substituées et leur utilisation

Publications (1)

Publication Number Publication Date
HK1198646A1 true HK1198646A1 (en) 2015-05-22

Family

ID=46197232

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112109.7A HK1198646A1 (en) 2011-05-06 2014-12-02 Substituted imidazopyridines and the use thereof

Country Status (8)

Country Link
US (1) US9150580B2 (fr)
EP (1) EP2705038A1 (fr)
JP (1) JP6100756B2 (fr)
CN (1) CN103842363B (fr)
CA (1) CA2834903A1 (fr)
DE (1) DE102011075398A1 (fr)
HK (1) HK1198646A1 (fr)
WO (1) WO2012152630A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015012571B1 (pt) 2012-11-30 2022-05-24 Astellas Pharma Inc Compostos de imidazopiridina e usos terapêuticos dos mesmos
WO2015106268A1 (fr) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de la sgc pour le traitement de troubles neuromusculaires
US20180169095A1 (en) 2015-05-06 2018-06-21 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
DK3325013T4 (da) 2015-07-23 2023-10-16 Bayer Pharma AG Stimulatorer og/eller aktivatorer af den opløselige guanylatcyklase (sgc) i kombination med en inhibitor af den neutrale endopeptidase (nep inhibitor) og en angiotensin aii-antagonist og deres anvendelse
CN108463224A (zh) 2015-12-14 2018-08-28 铁木医药有限公司 sGC刺激剂用于胃肠功能障碍治疗的应用
CN109890379A (zh) 2016-10-11 2019-06-14 拜耳制药股份公司 包含sGC活化剂和盐皮质激素受体拮抗剂的组合产品
EP3525779B1 (fr) 2016-10-11 2024-06-05 Bayer Pharma Aktiengesellschaft Combinaison contenant le stimulateur sgc vericugat et l'antagoniste des récepteurs minéralcorticoïdes finerenone
WO2018111795A2 (fr) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Utilisation de stimulateurs de sgc pour le traitement de la motilité œsophagienne
EP3609883B1 (fr) 2017-04-11 2022-06-29 Sunshine Lake Pharma Co., Ltd. Composés indazole substitués par fluor et leurs utilisations
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
EP3820476A1 (fr) 2018-07-11 2021-05-19 Cyclerion Therapeutics, Inc. Utilisation de stimulateurs gcs pour le traitement de maladies mitochondriales
WO2020164008A1 (fr) 2019-02-13 2020-08-20 Bayer Aktiengesellschaft Procédé de préparation de microparticules poreuses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
SI1869049T1 (sl) * 2005-03-21 2009-08-31 Lilly Co Eli Spojine imidazopiridazina
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
CN101981033B (zh) * 2008-02-06 2015-02-04 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102009004245A1 (de) * 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
WO2011119518A1 (fr) * 2010-03-25 2011-09-29 Merck Sharp & Dohme Corp. Activateurs de guanylate cyclase solubles

Also Published As

Publication number Publication date
US9150580B2 (en) 2015-10-06
EP2705038A1 (fr) 2014-03-12
CA2834903A1 (fr) 2012-11-15
CN103842363B (zh) 2017-09-26
US20140113900A1 (en) 2014-04-24
JP6100756B2 (ja) 2017-03-22
CN103842363A (zh) 2014-06-04
DE102011075398A1 (de) 2012-11-08
WO2012152630A1 (fr) 2012-11-15
JP2014513113A (ja) 2014-05-29

Similar Documents

Publication Publication Date Title
HK1190710A1 (zh) 氟烷基取代的吡唑並吡啶及其用途
HK1198698A1 (en) Substituted annellated pyrimidine and the use thereof
AP2014007731A0 (en) Substituted triazolopyridines and their use as TTKinhibitors
HK1198646A1 (en) Substituted imidazopyridines and the use thereof
GB201111705D0 (en) Compounds and their use
HK1191034A1 (en) N-carboxyalkyl-auristatins and use thereof n-
IL231082A (en) Pyrimido compounds - pyridazinone and their use
GB201111630D0 (en) Novel compounds and their use
EP2697386A4 (fr) Conception et utilisation de pepducine
GB201114448D0 (en) Compounds and their use
GB201004886D0 (en) The Hoppon
GB201115344D0 (en) The FitCase
HK1198587A1 (en) Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals -2-
GB201009016D0 (en) The SealCase
GB201115921D0 (en) The Denness fast-loo
GB201018845D0 (en) The gauntlag
GB2497001B (en) The hand
GB201204735D0 (en) The quadtrolley
GB201104444D0 (en) Compounds and their use
GB201120676D0 (en) The degravitator
GB201112500D0 (en) The degravitator
GB201112308D0 (en) The degravitator
GB201110618D0 (en) The gilabead
GB201110314D0 (en) The lughole
GB201108973D0 (en) The fledge